Vaccine and Antibody Production from Stem Cells, Vivalis

Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production.

Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions.

This interview was conducted at the NASDAQ Marketsite, on July 17th, 2008, in New York City.

Featuring:

• Dr. Majid Mehtali, CSO of Vivalis Reni Benjamin, Managing Director & Senior Biotechnology Analyst at Rodman & Renshaw
• Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV

DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

Related Videos:

1. Biological Processes & Industrial Production – Stem Cell Review (EP3)
2. Stem Cells at a Glance – Stem Cell Review (EP1)
3. Osiris CEO on the Applications of Mesenchymal Stem Cells
4. Stem Cells & Diabetes – Stem Cell Review (EP8)
5. I-Stem, Peschanski’s Stem Cell Technology Platform
6. Neural Stem Cells and CNS Disorder – Stem Cell Review (EP7)
7. Stem Cells (Best of the Web)
8. Mesenchymal Stem Cells and Connective Disorders – Stem Cell Review (EP6)